50 closest statements
by meaning · ranked by similarity · 100 per pageMeaning search returns the 50 nearest statements, then applies your filters.
“Our mission is to transform cancer care through the smart design and development of targeted solutions based on a deep understanding of cancer pathways and biological markers.”In use 2019 – now·1 sighting·SEC Form 10-K, filed 2019-03-0691% match
“Our mission is to target cancer and transform lives through the development of innovative cancer treatments.”In use 2005 – now·1 sighting·SEC Form 10-K, filed 2005-03-1677% match
“Our mission is to transform cancer treatment and prevention globally by driving technological innovation and accelerating the adoption of precision oncology medicine.”In use 2020 – now·1 sighting·SEC Form 424B4, filed 2020-06-2276% match
“Our mission is to transform the active management of cancer through personalized testing.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-02-2374% match
“Our mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of therapeutic agents.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-3074% match
“Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-1773% match
“Our mission is to transform cancer care.”In use 2018 – now·1 sighting·SEC Form 10-K, filed 2018-03-0773% match
“Our mission is to change the landscape of oncology drug discovery and enable the development of more effective therapies for the treatment of cancer.”In use 2025 – now·1 sighting·SEC Form S-1, filed 2025-07-1872% match
“Our mission is to build an oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0372% match
“Our mission is to provide a comprehensive and personalized approach to the clinical management of cancer through improved diagnostic, prognostic and therapeutic interventions.”In use 2010 – now·1 sighting·SEC Form 10-K, filed 2010-05-1771% match
“Our mission is to leverage an integrated and extensive genomics and transcriptomics discovery engine to identify antibodies targeted to newly discovered neoepitopes and to mobilize the human immune system of cancer patients to kill tumor cells and facilitate long-term remission.”In use 2017 – now·1 sighting·SEC Form 10-K, filed 2017-03-1571% match
“Our mission is to improve the lives of cancer patients by developing next-generation cancer therapies that are designed to maximize efficacy while minimizing the toxicity and side effects traditionally associated with cancer treatment.”In use 2020 – now·1 sighting·SEC Form 10-K, filed 2020-02-2171% match
“Our mission is to develop and manufacture intelligent diagnostic solutions that transform the power of diagnostics into a healthier future for everyone.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-02-2371% match
“Our mission is to build a leading oncology company that creates novel and transformative treatments for a wide range of oncology indications for which there are significant unmet medical needs.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-0771% match
“Our mission is to improve the lives of patients by developing novel therapeutics to treat some of the most devastating types of cancer.”In use 2026 – now·1 sighting·SEC Form 10-K/A, filed 2026-06-0270% match
“Our mission is to discover, develop and ultimately deliver medicines that are transformational for patients.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-2870% match
“Our mission is to make a meaningful impact on the lives of patients with cancer and high unmet medical needs by delivering novel, PRAME-directed immunotherapies that provide tangible clinical benefits.”In use 2026 – now·1 sighting·SEC Form 20-F, filed 2026-03-0570% match
“Our mission is to heal and empower cancer patients through compassion, innovation, and state-of-the-art medical care.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-2870% match
“Our mission is to leverage our unique insights into finding and binding cryptic functional pockets on currently intractable human biology-validated protein targets to discover, develop and commercialize small molecule therapies that can transform the lives of patients suffering from devastating cancers and immune disorders.”In use 2021 – now·1 sighting·SEC Form S-1, filed 2021-06-2570% match
“Our mission is to advance and grow a portfolio of innovative, early-stage oncology assets based on the latest scientific breakthroughs focused on overcoming immune resistance and expanding the addressable patient population.”In use 2023 – now·1 sighting·SEC Form 20-F, filed 2023-07-3170% match
“Our mission is to transform cancer treatment by delivering innovative radioconjugates that maximize therapeutic efficacy while minimizing toxicity to healthy tissue by combining our deep understanding of tumor biology and translational medicine with our expertise in radiochemistry.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-3070% match
“Our mission is to leverage our unique insights into the chromatin regulatory system to pioneer the discovery, development and commercialization of a new class of therapies that transform the lives of patients suffering from a wide spectrum of diseases with high unmet need.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1170% match
“Our mission is to discover and develop effective biologic treatments applicable to a range of challenging, validated targets with high potential to help people with life-threatening conditions.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1970% match
“Our mission is to become a global leader in developing better and safer radioimmunotherapy and antibody-based oncology therapies addressing clear unmet medical needs and, as such, have a transformational impact on the lives of patients.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-03-0470% match
“Our mission is to build a breakthrough oncology company creating neoantigen-based therapies that significantly improve the lives of patients.”In use 2018 – now·1 sighting·SEC Form 424B4, filed 2018-06-2870% match
“Our mission is to accelerate scientific and medical breakthroughs and deliver well-tolerated medicines with greater efficacy and safety to people with the deadliest cancers.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0570% match
“Our mission is to transform the field of proteomics by broadening access to high-quality proteomic data and to help support fundamental advancements across human health and medicine.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2670% match
“Our mission is to unite biopharma, physicians, and patients to transform the standard of care and improve outcomes with personalized diagnostics.”In use 2024 – now·1 sighting·SEC Form S-1/A, filed 2024-05-2469% match
“Our mission is to accelerate transformative therapies to improve the lives of people living with cancer and other serious diseases.”In use 2017 – now·1 sighting·SEC Form 10-K, filed 2017-02-2369% match
“Our mission is to help improve the lives of those affected by cancer through translating cancer discoveries into better patient care.”In use 2010 – now·1 sighting·SEC Form 10-K, filed 2010-03-1669% match
“Our mission is to empower physicians to positively impact patient care through the delivery of innovative molecular diagnostics services.”In use 2013 – now·1 sighting·SEC Form 10-K, filed 2013-03-2569% match
“Our mission is to develop a portfolio of innovative product candidates for the treatment of cancer.”In use 2022 – now·1 sighting·SEC Form 424B4, filed 2022-02-0769% match
“Our mission is to leverage unique insights into protein motion to transform the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of small molecule therapies.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2669% match
“Our mission is to enable customers across the continuum of molecular research and clinical testing to unlock valuable insights faster, better and more efficiently - from the raw biological sample to the final interpreted results.”In use 2022 – now·1 sighting·SEC Form 20-F, filed 2022-03-1469% match
“Our mission is to combine the ingenuity of people with the power of data and technology to achieve new victories against cancer.”In use 2020 – now·1 sighting·SEC Form 10-K, filed 2020-11-2569% match
“Our mission is to build an ecosystem that spans the entire treatment process, spanning from early screening and diagnosis to robotic-assisted ablation and posttreatment care.”In use 2026 – now·1 sighting·SEC Form 20-F/A, filed 2026-07-2769% match
“Our mission is to offer an ecosystem of innovative discovery and translational research solutions that enable our customers to map the universe of biology and conduct scientific exploration that may lead to new therapies to improve the human condition.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-02-2869% match
“Our mission is to inspire hope for those battling cancer by expanding on the promise of targeted therapies.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-03-1569% match
“Our mission is to improve overall patient condition through innovative bio-immunotherapy with proven treatment protocols, to lower deaths associated with cancer and to reduce the cost of cancer treatment.”In use 2020 – now·1 sighting·SEC Form 10-K, filed 2020-03-2569% match
“Our mission is to improve the delivery of healthcare and optimize patient outcomes by leveraging the latest advancements in precision medicine and software technology to enable true value-based care.”In use 2019 – now·1 sighting·SEC Form 10-K, filed 2019-04-0169% match
“Our mission is to create therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-04-1668% match
“Our mission is to advance novel therapies, leveraging evidence-based innovation, with the potential to transform the lives of people suffering from serious, chronic conditions and unmet medical needs.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-09-2568% match
“Our mission is to become a leader in bringing innovative cancer treatments to the market and to improve patient health outcomes.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-03-2068% match
“Our mission is to improve the quality of life of people suffering from cancer and to increase shareholder value by commercializing our platform technologies through in-house development, joint ventures, strategic alliances and licensing arrangements.”In use 2003 – now·1 sighting·SEC Form 10-K, filed 2003-07-2968% match
“Our mission is to be the foremost biopharma company interrogating ecDNA biology to deliver transformative therapies that improve and extend the lives of patients with previously intractable oncogene amplified cancers.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0968% match
“Our mission is to improve health with technologies that transform the way that antibody-based therapies are discovered.”In use 2022 – now·1 sighting·SEC Form 10-K, filed 2022-02-2568% match
“Our mission is to create, develop, manufacture, and deliver cell and gene therapies to transform the lives of people impacted by life-threatening diseases.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-1868% match
“Our mission is to discover and develop novel therapeutics to address significant medical needs.”In use 2007 – now·1 sighting·SEC Form 10-K, filed 2007-03-1968% match
“Our mission is to be the global leader and pioneer of this new treatment paradigm, integrating recombinant technology, gene therapy and cell therapy to address the challenges of targeting and delivering effective therapies, including to the brain for cancer and other central nervous system (“CNS”) indications.”In use 2026 – now·1 sighting·SEC Form S-1, filed 2026-08-2868% match
“Our mission is to address the pervasive problem of cancer misdiagnoses by developing solutions in the form of diagnostic products and services.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-03-2768% match
Showing 1–50 of 50